Hints and tips:
Related Special Reports
...& Johnson subsidiary Janssen Pharmaceuticals....
...Pfizer has invited other pharmaceutical companies to join the initiative, which is partly funded by the Bill & Melinda Gates Foundation, and asked governments, global health authorities and philanthropists...
...Janssen is the pharmaceutical division of J&J....
...In 2020, Pfizer spun off its generics business Upjohn, combining it with Mylan to form Viatris, while Johnson & Johnson, GSK, Pfizer and Novartis have all shed their consumer health businesses selling over-the-counter...
...Horizon had also attracted interest from French drugmaker Sanofi and US pharma group Johnson & Johnson....
...Ginger Graham, a board member since 2010 and former chief of Amylin Pharmaceuticals, will fill the chief executive role while it searches for “a successor with deep healthcare experience”....
...Late on Tuesday, an affiliate of Johnson & Johnson filed for bankruptcy protection....
...The FT’s US pharmaceutical correspondent Jamie Smyth helps us explore whether J&J’s use of this manoeuvre is setting a precedent for corporations to evade accountability in America....
...Johnson & Johnson reported a first-quarter loss as it booked a $6.9bn charge linked to its proposal to settle tens of thousands of legal claims related to allegations its talcum powder caused cancer....
...Shares of Kenvue, the consumer arm of healthcare giant Johnson & Johnson, jumped on their first day of trading after an upsized initial public offering that marked the biggest US listing in almost 18 months...
...But mild over-the-counter remedies have lost their power to make shareholders in Johnson & Johnson feel good....
...I think a lot of people were anticipating a V-shaped recovery . . . People are now waking up the realisation that volatility is going to be normal going forward.”...
...Risk management Winner: Johnson & JohnsonOriginality: 8; Leadership: 9; Impact: 9; Total: 26The litigation team in Asia-Pacific designed a digital system for the pharmaceutical business to improve its management...
...When Joaquin Duato delivered his first annual results as chief executive and chair of Johnson & Johnson last month, he enthused about being “excited for the future” of the company, which is poised to spin...
...Johnson & Johnson has agreed to buy cardiovascular technology group Abiomed for $16.6bn, including debt, a sign that mega dealmaking remains robust in the US despite geopolitical and economic uncertainty...
...A coalition of ethical investors have asked Johnson & Johnson, Merck, Pfizer, Eli Lilly, Gilead, Amgen, Regeneron, Bristol Myers Squibb and AbbVie to publish a report on the process they follow when applying...
...Johnson & Johnson announced in November it had struck a deal to acquire cardiovascular technology group Abiomed for $16.6bn, while Pfizer said in May it had agreed to buy US biotech Biohaven Pharmaceuticals...
...Johnson & Johnson thinks there is money to be made in the cardiovascular field....
...To beat out Johnson & Johnson and Sanofi, Amgen will be paying nearly 45 times EV to ebitda for Horizon. The wider S&P Biotech index trades on a multiple of 11.4 times....
...Horizon’s assets, which include treatments for chronic gout and neuromyelitis optica, a disease affecting the central nervous system, had also attracted interest from Johnson & Johnson and Sanofi....
...Johnson & Johnson trimmed its full-year profit forecast for the second time in consecutive quarters, as a surge in the value of the dollar depresses sales reported outside the US....
...Janssen, the pharmaceuticals division of J&J, and Pfizer both started their phase 3 trials in September last year....
...Johnson & Johnson, one of the world’s largest healthcare companies, is facing thousands of lawsuits from people alleging they got cancer from using one of their oldest products: talc-based baby powder....
...The virus is one of the few major infectious diseases without a vaccine, although recent scientific advances have encouraged four large pharmaceutical companies — Pfizer, GSK, Johnson & Johnson and Moderna...
...McKee was a senior executive at Janssen Pharmaceuticals, a division of Johnson & Johnson....
International Edition